
1. plos one. 2013 may 20;8(5):e64200. doi: 10.1371/journal.pone.0064200. print 2013.

a herpes simplex virus-derived replicative vector expressing lif limits
experimental demyelinating disease modulates autoimmunity.

nygårdas m(1), paavilainen h, müther n, nagel ch, röyttä m, sodeik b, hukkanen v.

author information: 
(1)department virology, university turku, turku, finland.
michaela.nygardas@utu.fi

herpes simplex virus type 1 (hsv-1) properties exploited 
development gene therapy vectors. neurotropism hsv enables delivery 
therapeutic genes nervous system. using bacterial artificial chromosome 
(bac), constructed hsv-1(17(+))-based replicative vector deleted the
neurovirulence gene γ134.5, expressing leukemia inhibitory factor (lif) 
transgene treatment experimental autoimmune encephalomyelitis (eae). eae
is inducible t-cell mediated autoimmune disease central nervous system 
(cns) used animal model multiple sclerosis. demyelination and
inflammation hallmarks diseases. lif cytokine the
potential limit demyelination oligodendrocyte loss cns autoimmune
diseases affect t-cell mediated autoimmune response. study
sjl/j mice, induced eae, treated hsv-lif vector intracranially
and subsequent changes disease parameters immune responses 
acute disease investigated. replicating hsv-lif dna detected in
the cns acute infection, vector spread spinal cord 
was non-virulent. hsv-lif significantly ameliorated eae contributed
to higher number oligodendrocytes brains compared untreated
mice. hsv-lif therapy also induced favorable changes expression of
immunoregulatory cytokines t-cell population markers cns the
acute disease. data suggest bac-derived hsv vectors suitable for
gene therapy cns disease used test therapeutic potential 
immunomodulatory factors treatment eae.

doi: 10.1371/journal.pone.0064200 
pmcid: pmc3659099
pmid: 23700462  [indexed medline]

